Myasthenia gravis trials in United States

In United States 52 Also abroad 123

52 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Amherst, Cincinnati, Columbus, Greenfield, O'Fallon, Scottsdale
Age
18 years and over
People
120 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07463521 · EU 2025-524756-54-00
Phase 3Taking people
A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
Where
Columbus, Scottsdale
Age
18 years and over
People
100 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT07465289 · EU 2025-524757-14-00
Phase 3Taking people
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
Where
Augusta, Aurora, Boca Raton, Boston, Burlington, Charleston, Cincinnati, Cleveland, Columbus, Cordova, Dallas, Durham, Jacksonville, Kansas City, Los Angeles, New Haven, Palo Alto, Paradise Valley, Pasadena, Port Charlotte, Scottsdale, St Louis, Tampa
Age
18 years and over
People
199 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT04951622 · EU 2023-504152-97-00
Phase 2/3Taking people
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
Where
Chicago, Denton
Age
12 years to 17 years
People
8 worldwide
Run by
UCB Biopharma SRL
See details and how to joinNCT06055959 · EU 2022-502072-23-00
Phase 2/3Taking people
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
Where
Ann Arbor, Aurora, Hershey, Lawrence, Los Angeles, Palo Alto, Philadelphia, Phoenix, Pittsburgh, San Francisco, Tampa
Age
2 years to 17 years
People
12 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT05265273 · EU 2022-502539-21-00
Phase 2Taking people
ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
Where
Amherst, Austin, Carlsbad, Chattanooga, Las Vegas, Miami
Age
18 years and over
People
40 worldwide
Run by
argenx
See details and how to joinNCT07673627 · EU 2025-522939-33-00
Phase 2/3Enrolling by invitation
Evaluating Long-term Safety of Efgartigimod Administered Intravenously and Efgartigimod PH20 Administered Subcutaneously in Children With Generalized Myasthenia Gravis
Where
Charlotte, Charlottesville, Chicago
Age
2 years to 18 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT05374590 · EU 2023-507379-23-00
Phase 3Taking people
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
Where
Austin, Boca Raton, Colorado Springs, Cordova, Dallas, Detroit, East Lansing, Farmington, Fort Collins, Foxborough, Fullerton, Houston, Indianapolis, Kirkland, New Orleans, New York, O'Fallon, Pomona, Raleigh, Winston-Salem
Age
18 years to 74 years
People
115 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07217587 · EU 2025-521130-28-00
Phase 3Taking people
A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
Where
Boca Raton, Fayetteville, Houston, Pasadena
Age
18 years to 80 years
People
195 worldwide
Run by
Dianthus Therapeutics
See details and how to joinNCT07647510 · EU 2026-525298-38-00
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
Where
Clearwater, Colorado Springs, Farmington Hills, Greenville, Maitland, New Bern
Age
18 years and over
People
120 worldwide
Run by
TG Therapeutics, Inc.
See details and how to joinNCT07673744 · EU 2025-524630-26-00
No phaseTaking people
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Where
Sioux Falls
People
20,000
Run by
Sanford Health
See details and how to joinNCT01793168
Phase 1Taking people
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
Where
Ann Arbor, Cleveland, Columbus, La Jolla, Milwaukee, New York, Omaha, Rochester
Age
18 years and over
People
100
Run by
TG Therapeutics, Inc.
See details and how to joinNCT06680037
No phaseTaking people
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
Where
Amherst, Austin, Boston, Carlsbad, Chapel Hill, Chattanooga, Cincinnati, Columbus, Detroit, Durham, Las Vegas, Miami, San Antonio, Tampa
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07294170
Phase 2Taking people
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Where
Austin, Chicago, Philadelphia, Seattle
Age
2 years to 17 years
People
15 worldwide
Run by
Amgen
See details and how to joinNCT06987539 · EU 2025-520993-20-00
Phase 1Taking people
Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related Diseases
Where
Columbus, Dallas, Detroit, Houston, Los Angeles, Minneapolis, New York, Orange, Palo Alto, Philadelphia, Portland, Rochester, Tampa
Age
18 years and over
People
30
Run by
Kite, A Gilead Company
See details and how to joinNCT06626919
Phase 3Taking people
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Where
Altamonte Springs, Boca Raton, Burlington, Centerville, Chapel Hill, Charleston, Chattanooga, Cincinnati, Dallas, El Paso, Falls Church, Farmington, Greenfield, Jacksonville, Kansas City, Longmont, Maitland, McKinney, Phoenix, Tampa, Washington D.C., Winston-Salem
Age
18 years and over
People
264 worldwide
Run by
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
See details and how to joinNCT06463587 · EU 2023-507746-83-00
Phase 1/2Taking people
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Where
Aurora, Boston, Chicago, Houston, Jacksonville, Kansas City, New York, Orange, Portland, Rochester, Sacramento, San Francisco, Seattle, Worcester
Age
18 years to 70 years
People
24
Run by
Cabaletta Bio
See details and how to joinNCT06359041
Phase 1Taking people
Study of KITE-363 in Participants With Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment
Where
Newport Beach, New York, Palo Alto, Salt Lake City, Seattle
Age
18 years to 75 years
People
57 worldwide
Run by
Kite, A Gilead Company
See details and how to joinNCT07304154
No phaseNot yet taking people in United States
Quantification of Change in MG Disease Activity in Individuals With Generalized Myasthenia Gravis (gMG) After Administration of VYVGART® or VYVGART Hytrulo® Using BioDigit MG
Where
Boston
Age
18 years to 80 years
People
25
Run by
BioSensics
See details and how to joinNCT07226830
No phaseTaking people
Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
Where
Washington D.C.
Age
18 years and over
People
18
Run by
George Washington University
See details and how to joinNCT07787247
Phase 2/3Taking people
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
Where
Charlotte, Charlottesville, Denton
Age
2 years to 17 years
People
12 worldwide
Run by
argenx
See details and how to joinNCT06392386 · EU 2023-506159-12-00
Phase 2Taking people
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
Where
Amherst, Austin, Boston, Carlsbad, Chapel Hill, Chattanooga, Cincinnati, Columbus, Detroit, Durham, Las Vegas, Miami, San Antonio, Tampa
Age
18 years and over
People
70 worldwide
Run by
argenx
See details and how to joinNCT07284420 · EU 2025-522492-28-00
Phase 3Taking people
Zilucoplan for Severe gMG Exacerbations
Where
Columbus, Kansas City, Tampa
Age
18 years and over
People
15
Run by
Miriam Freimer
See details and how to joinNCT07215949
No phaseEnrolling by invitation
PPDTM CorEvitasTM Myasthenia Gravis (MG) Drug Safety and Effectiveness Registry
Where
Waltham
Age
18 years and over
People
1,500
Run by
CorEvitas
See details and how to joinNCT07217509
Phase 2Taking people
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
Where
Augusta, Aurora, Boca Raton, Carlsbad, Chapel Hill, Columbia, Columbus, Irvine, Memphis, Portland, Tampa
Age
18 years and over
People
84 worldwide
Run by
NMD Pharma A/S
See details and how to joinNCT06414954